Biolinerx Stock Performance
| BLRX Stock | USD 0.27 0.01 3.57% |
The firm shows a Beta (market volatility) of -0.46, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning BioLineRx are expected to decrease at a much lower rate. During the bear market, BioLineRx is likely to outperform the market. At this point, BioLineRx has a negative expected return of -1.09%. Please make sure to confirm BioLineRx's jensen alpha, skewness, as well as the relationship between the Skewness and day typical price , to decide if BioLineRx performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days BioLineRx has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain fairly strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
| Begin Period Cash Flow | 10.6 M |
BioLineRx |
BioLineRx Relative Risk vs. Return Landscape
If you would invest 65.00 in BioLineRx on August 28, 2024 and sell it today you would lose (38.00) from holding BioLineRx or give up 58.46% of portfolio value over 90 days. BioLineRx is currently does not generate positive expected returns and assumes 6.9474% risk (volatility on return distribution) over the 90 days horizon. In different words, 61% of stocks are less volatile than BioLineRx, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
BioLineRx Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for BioLineRx's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as BioLineRx, and traders can use it to determine the average amount a BioLineRx's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1574
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | BLRX |
Estimated Market Risk
| 6.95 actual daily | 61 61% of assets are less volatile |
Expected Return
| -1.09 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.16 actual daily | 0 Most of other assets perform better |
Based on monthly moving average BioLineRx is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BioLineRx by adding BioLineRx to a well-diversified portfolio.
BioLineRx Fundamentals Growth
BioLineRx Stock prices reflect investors' perceptions of the future prospects and financial health of BioLineRx, and BioLineRx fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on BioLineRx Stock performance.
| Return On Equity | -1.72 | ||||
| Return On Asset | -0.35 | ||||
| Profit Margin | (1.77) % | ||||
| Operating Margin | (1.07) % | ||||
| Current Valuation | 25.74 M | ||||
| Shares Outstanding | 79.94 M | ||||
| Price To Earning | (3.88) X | ||||
| Price To Book | 1.59 X | ||||
| Price To Sales | 1.30 X | ||||
| Revenue | 4.8 M | ||||
| EBITDA | (57.06 M) | ||||
| Cash And Equivalents | 43.15 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 11.59 M | ||||
| Debt To Equity | 0.05 % | ||||
| Book Value Per Share | 0.01 X | ||||
| Cash Flow From Operations | (22.61 M) | ||||
| Earnings Per Share | (0.45) X | ||||
| Total Asset | 63.92 M | ||||
| Retained Earnings | (390.61 M) | ||||
| Current Asset | 48.18 M | ||||
| Current Liabilities | 3.14 M | ||||
About BioLineRx Performance
Evaluating BioLineRx's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if BioLineRx has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if BioLineRx has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
BioLineRx Ltd., a clinical-stage biopharmaceutical development company, focuses on oncology. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modiin, Israel. Biolinerx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 38 people.Things to note about BioLineRx performance evaluation
Checking the ongoing alerts about BioLineRx for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for BioLineRx help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| BioLineRx generated a negative expected return over the last 90 days | |
| BioLineRx has high historical volatility and very poor performance | |
| BioLineRx has some characteristics of a very speculative penny stock | |
| BioLineRx has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 4.8 M. Net Loss for the year was (60.61 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| BioLineRx currently holds about 43.15 M in cash with (22.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| BioLineRx has a frail financial position based on the latest SEC disclosures |
- Analyzing BioLineRx's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether BioLineRx's stock is overvalued or undervalued compared to its peers.
- Examining BioLineRx's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating BioLineRx's management team can have a significant impact on its success or failure. Reviewing the track record and experience of BioLineRx's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of BioLineRx's stock. These opinions can provide insight into BioLineRx's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for BioLineRx Stock Analysis
When running BioLineRx's price analysis, check to measure BioLineRx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioLineRx is operating at the current time. Most of BioLineRx's value examination focuses on studying past and present price action to predict the probability of BioLineRx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioLineRx's price. Additionally, you may evaluate how the addition of BioLineRx to your portfolios can decrease your overall portfolio volatility.